Enes Yeşilbaş

Honored and grateful to be among the 2026 Conquer Cancer Grants & Awards recipients. Thank you, @ConquerCancerFd and @ASCO for investing in the next generation of oncology researchers and leaders. Looking forward to #ASCO26 in Chicago! 🎗️🌍

#ResearchConquersCancer #ConquerCancer #ASCO26 #CancerResearch #Oncology #GlobalOncology #CancerCare #FutureOfOncology

📢 I’m pleased to share that our ZINCLO-HAND study has been published in @JCOOP_ASCO JCO Oncology Practice.

🔬 In this prospective, nonrandomized study across 13 oncology centers in Türkiye, we compared oral zinc, topical clobetasol, and their combination for the prevention of regorafenib-induced hand–foot skin reaction (HFSR). Of 179 enrolled patients, 156 were evaluable for the primary end point.

📊 Grade ≥2 HFSR within 8 weeks (overall P = .016)

16.4% with oral zinc plus topical clobetasol
38.8% with oral zinc alone
38.5% with topical clobetasol alone

💊 HFSR-related dose reductions or temporary interruptions occurred in 12.7%, 30.6%, and 28.8%, respectively. Median relative dose intensity was similar across groups. These findings warrant confirmation in a randomized study.

🙏 My thanks to our first author, Dr. Orhun Akdoğan (@drOrhunakdogan) , for his dedication, to our mentor, Dr. Osman Sutcuoglu (@osutcuoglu), for his scientific guidance and leadership, and to our colleagues across all 13 centers.

🔗 doi.org/10.1200/OP-26-…

@RyanNipp, @thenasheffect,
@crisbergerot, @minasedrakmd,
@uyargalip · @kbaskurtt · @yucelbirkadriye
@ASCO, @JCO_ASCO, @EthicsdoctorP
#ZINCLOHAND #SupportiveCare #MedicalOncology #Regorafenib #JCOOncologyPractice

🔬 Four important discussions from the final Presidential Sessions at #ESMO26!

💊 KEYNOTE-C93: Pembrolizumab monotherapy improved PFS in dMMR advanced or recurrent endometrial cancer, although the prespecified non-inferiority criterion was not met. An important step toward chemotherapy-free treatment.

🎯 Sacituzumab tirumotecan (sac-TMT): Impressive results in previously treated endometrial cancer, with improved PFS (7.2 vs 3.9 months) and OS (19.0 vs 12.1 months). ADCs are clearly changing the landscape!

🧬 MOIO trial: Can we safely extend immunotherapy intervals to every 3 months? The trial stopped early, leaving the question statistically unresolved and highlighting the challenges of treatment de-escalation.

📊 Non-inferiority: Who decides how much efficacy we can afford to lose? A great reminder that statistical margins must also reflect clinical judgment and patient preferences.

Four discussions that could shape how we design trials and treat patients in the coming years. 💚

@osutcuoglu @uyargalip @kbaskurtt
@tubaugurdr @drOrhunakdogan
@myESMO

#ESMO26 #ESMO2026 #Oncology #Immunotherapy #EndometrialCancer #ADC #ClinicalTrials

Great to finally meet Dr. Sumanta Pal at #ESMO26💚 His contributions to GU oncology have been truly remarkable. So much to learn from his work!

@montypal @kbaskurtt
@myESMO

💚 So happy to be featured in ESMO’s #ESMOcommunity video at #ESMO26 🌍

💫 More than science, oncology is about people, friendships, and a shared passion for better cancer care.

🙏 Thank you, @myESMO, for including me in this amazing community!

@FLordick28391 @YJanjigianMD
@MartinReck2 @FAndreMD
@osutcuoglu @uyargalip @kbaskurtt

#ESMO2026 #Oncology #CancerResearch #MedicalOncology #CancerCare #GlobalOncology #YoungOncologists #Madrid2026